Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Washington University School of Medicine
498 trials monitored
See 39 trials at risk
Heart Disease
8,814 trials monitored
See 428 trials at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
and 1 more disease
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
Trial Details
NCT Number NCT07838649
Lead Sponsor Washington University School of Medicine
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Related terms Breast Neoplasms, Cardiotoxicity, Cardiovascular Diseases, Hodgkin Disease, Lymphoma, Non-Hodgkin
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov